On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details

NetworkNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) Lead Compound XPro1595 Data to be Presented at the Society for Neuroscience’s Annual Meeting

INmune Bio, Inc. (NASDAQ: INMB) today announced a poster presentation related to its program in Alzheimer’s disease at the upcoming Society for Neuroscience (“SfN”) 49th Annual Meeting to be held at McCormick Place in Chicago from Oct. 19–23, 2019. The company also announced that its poster was selected for presentation during the meeting’s press conference. … Continue reading “NetworkNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) Lead Compound XPro1595 Data to be Presented at the Society for Neuroscience’s Annual Meeting”

NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Second Annual Advances in Immuno-Oncology USA Congress and World Immunotherapy Congress

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that its Co-Founder and CEO RJ Tesi, M.D., will present at the 2nd Annual Advances in Immuno-Oncology USA Congress taking place on October 8-9 in San Diego. In addition, Dr. Tesi … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Second Annual Advances in Immuno-Oncology USA Congress and World Immunotherapy Congress”

NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) CEO Discusses Company Achievements in Interview; Director of Neuroscience to Present at World Immunotherapy Congress

RJ Tesi, M.D., co-founder and CEO of clinical-stage immunology company INmune Bio (NASDAQ: INMB), was recently featured in an interview with multimedia financial reporter Jason Lin. Among other highlights, Dr. Tesi discusses recent company accomplishments in the interview. “Nasdaq’s MarketSite is a premiere platform for INmune Bio to share our story with investors and to … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) CEO Discusses Company Achievements in Interview; Director of Neuroscience to Present at World Immunotherapy Congress”

NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at 2019 AAIC Satellite Symposium

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its plans to present at the upcoming Alzheimer’s Association International Conference (“AAIC”) Satellite Symposium to be held in held Sydney, Australia from September 25-27, 2019. According to the update, INmune … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at 2019 AAIC Satellite Symposium”

NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Executives to Speak, Showcase Innate Compounds at Two Upcoming Events

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder and CEO, and Mark Lowdell, Ph.D., Co-Founder and Chief Scientific Officer, will be presenting at the first ever Targeting Innate Immunity Congress. Dr. Tesi and Dr. … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Executives to Speak, Showcase Innate Compounds at Two Upcoming Events”

NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives USPTO Allowance of Key Patent Covering DN-TNFa Platform Technology for Treating Cancer

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its receipt of United States Patent and Trademark Office (“USPTO”) formal notice of allowance to Patent Application Serial No. 15/776,061. The patent, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives USPTO Allowance of Key Patent Covering DN-TNFa Platform Technology for Treating Cancer”

NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Reports Positive Q2 2019 Financial Results

INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, recently reported financial results for the second quarter ended June 30, 2019 (http://nnw.fm/KnIw1). An article discussing the company reads, “Apart from announcing strategic developments, INmune Bio also presented its most important financial results for the … Continue reading “NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Reports Positive Q2 2019 Financial Results”

NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Advances Clinical Development of INB03

INmune Bio (NASDAQ: INMB) co-founder and CEO Dr. RJ Tesi recently reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients during a presentation at Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston (http://nnw.fm/Wu2Ao). An article discussing the company reads, “‘The goal of the Phase I study is to determine, … Continue reading “NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Advances Clinical Development of INB03”

INmune Bio Inc. (NASDAQ: INMB) Announces Continuous Advancement of Clinical Program, New Strategic Appointment

The immunology company released its financial results for the second quarter of 2019 and also delivered an update on its clinical trials The phase I trial of INmune Bio’s cancer treatment INB03 has delivered promising results in terms of safety and tolerability. The company will now be moving forward with the phase II of the … Continue reading “INmune Bio Inc. (NASDAQ: INMB) Announces Continuous Advancement of Clinical Program, New Strategic Appointment”

NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Releases Q2 2019 Financial Results, Provides Shareholder Update

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its financial results for the second quarter ended June 30, 2019 and also provided a year-to-date business update. “This year we remained focused on advancing our pipeline,” INmune Bio CEO RJ … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Releases Q2 2019 Financial Results, Provides Shareholder Update”

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217